To Get more Insights,  Request A Free Sample 

Emerging Opportunities Reshaping Ureteral Stents Market Dynamics

• A significant opportunity lies in the development of patient-specific ureteral stents using additive manufacturing. Standardized stent sizes often lead to poor anatomical fit, causing significant pain and discomfort. 3D printing technology allows for the creation of stents customized to a patient’s unique ureteral length and curvature, based on pre-operative imaging. A 2024 clinical study highlighted that these custom-fit stents can reduce patient-reported pain scores by an average of 3 points on a visual analog scale compared to conventional stents. Companies mastering on-demand, customized manufacturing will hold a substantial competitive advantage.
• Another major growth frontier is the integration of digital health platforms for remote patient monitoring. Post-procedural care for ureteral stent patients is often reactive. A new trend in the ureteral stents market involves providing patients with mobile applications to log symptoms in real-time using validated tools like the Ureteral Stent Symptom Questionnaire (USSQ). A 2025 pilot program for one such remote monitoring application demonstrated a 25% reduction in unscheduled clinic visits for stent-related concerns. Creating an ecosystem that pairs a physical stent with a digital monitoring service offers a powerful value proposition for healthcare systems focused on efficiency and improved patient satisfaction.

Outpatient Shift and Procedural Efficiency Fuel Explosive Demand in ASCs

A seismic shift toward outpatient settings is fundamentally reshaping demand within the ureteral stents market. Ambulatory Surgical Centers (ASCs) have become a focal point for growth, driven by cost-effectiveness and efficiency. In 2024 alone, 67 new ASCs became Medicare-certified between the second and third quarters, expanding procedural capacity nationwide. The quality of care in these centers is gaining recognition, with 63 urology ASCs named as high-performers by U.S. News in 2025. This momentum has attracted significant investment, highlighted by major private equity deals in 2024 involving large urology groups, including one network operating approximately 24 ASCs. The trend is further supported by the acquisition of 45 new centers by USPI, the nation's largest ASC operator, in 2024.

The financial and operational advantages of ASCs are quantifiable drivers of demand in the ureteral stents market. A 2025 Medicare reimbursement of $5,083.62 for a complex ureteroscopy with stent insertion provides a stable payment structure. Patient affordability is also a key factor, with average out-of-pocket savings reaching $2,454 for certain procedures compared to hospital settings. This efficiency is enabled by procedure-specific innovations. Sales of single-use ureteroscopes, crucial for ASCs, reached a value of $70.5 million in North America in 2024. The ecosystem is also adapting, with 1 new CPT code for a specialized urology procedure introduced for 2024. The scale of these ASC-centric practices is substantial, with one leading group supporting 250 physicians, solidifying the outpatient setting as a critical demand center for the ureteral stents market.

Advanced Stent Technology Focuses Directly on Improving Patient-Reported Outcomes

Innovation in the ureteral stents market is now intensely focused on improving the patient experience, a trend validated by large-scale clinical research. The demand for less invasive and morbid solutions is driving major studies, such as the SOUL trial, which has a target enrollment of 792 patients to compare stenting versus omission. As of March 2025, 204 patients had already joined its randomized cohort. Evidence-based demand is also being shaped by head-to-head device comparisons. The BLUES clinical trial, which completed enrollment of 250 patients, is directly comparing new silicone stents against traditional polyurethane ones over a median duration of 8 days to assess patient-reported outcomes.

Specific technological advancements are addressing long-standing patient complaints in the ureteral stents market. A 2024 study on a magnetic removal stent system, involving 100 patients, demonstrated a significant reduction in pain, with a score of 2 versus 6 for traditional removal. The same technology cut the removal procedure time by 116.7 seconds. The industry's focus on patient experience is standardized by the 38-item Ureteral Stent Symptom Questionnaire (USSQ), a tool now central to clinical validation. The urgency for better devices is underscored by safety data; a 2024 analysis of the FDA MAUDE database revealed 2652 adverse event reports over a decade, with 627 reports specifically citing stent breakage. Such figures create powerful demand for more durable and patient-friendly ureteral stents.

 Segmental Analysis 

Polymer Stents A Cost-Effective Solution Driving Market Dominance

The ureteral stents market is overwhelmingly shaped by the leadership of polymer-based devices, which hold a commanding 71% share. The preference for materials like polyurethane and silicone stems from their superior flexibility, inherent biocompatibility, and significant cost advantages over metallic alternatives. Hospitals and surgical centers favor these stents for their ease of placement and the improved comfort they offer patients during indwelling periods that can range from 15 to 60 days. This widespread adoption is a key pillar of the modern ureteral stents market, enabling a high volume of procedures to be performed efficiently and affordably.

Continued innovation keeps polymer stents at the forefront. A study involving 220 patients highlighted their versatility across numerous urological operations, reinforcing their status as a go-to solution for surgeons. While side effects are noted in over 80% of cases, the fundamental benefits of reliable drainage and obstruction prevention secure their dominant position. The development of advanced polymer formulations and specialized coatings that reduce infection risk and encrustation further cements their value proposition in a competitive healthcare landscape.

• Modern silicone stents have been re-engineered with stronger tensile strengths to overcome earlier limitations.
• Hydrophilic coatings are a key innovation, improving lubrication and biocompatibility for polymer stents.
• Polyurethane is often chosen as it blends the softness of silicone with the hardness of polyethylene.

Kidney Stone Treatment A Primary Demand Driver for Stents

Fueling the growth of the ureteral stents market is the high-volume application in kidney stone management, accounting for over 41% of stent use. The global prevalence of kidney stones is on the rise, with rates in North America at approximately 9.3% and parts of Asia reaching as high as 17.6%. Ureteral stents are indispensable in these cases, providing immediate relief from obstructions and preventing severe complications. Procedures to treat kidney stones, such as ureteroscopy, have surged, with one region seeing a 158% increase over 17 years; stents are used in up to 80% of these cases to ensure proper healing and drainage.

The sheer number of individuals affected—11% of men and 6% of women in the U.S. alone—translates directly into sustained demand for ureteral stents. With climate change models predicting a potential increase in the at-risk population to 70% by 2095, the need for effective stone management is set to grow. This essential application ensures that the ureteral stents market remains robust and closely tied to the epidemiological trends of urolithiasis, making it a critical segment for device manufacturers.

• Stents are placed after ureteroscopy to prevent ureteral obstruction from postoperative swelling.
• They serve as a crucial tool to bypass blockages, drain infections, and allow the ureter to heal.
• Climate-related factors are expected to significantly increase kidney stone events in the coming decades.

Regional Analysis 

North America's Dominance Is Fueled by Robust Infrastructure and High Innovation

North America commands the ureteral stents market with over 39% market share, a position sustained by its unparalleled healthcare infrastructure and relentless pace of innovation. The U.S. healthcare system's depth is evident, with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a key funder of urology research, operating with a $2.45 billion budget in fiscal year 2024. The pipeline of specialists remains strong; the 2024 Urology Match offered 385 residency positions across the country. Regulatory pathways are active, with the FDA's Center for Devices and Radiological Health (CDRH) reporting 24 novel medical device approvals in 2024, several of which are relevant to urology.

The innovation ecosystem is further supported by a strong intellectual property framework in the ureteral stents market, which saw 82 new patents granted for ureteral stent designs and materials in the U.S. in 2024. The Canadian market contributes significantly, with its 982 registered urologists serving the population. Procedural volume is high, with an estimated 1.3 million shock wave lithotripsy procedures performed annually in the U.S., many requiring subsequent stenting. The research landscape is vibrant, with 21 new clinical trials for urological disorders initiated at major U.S. academic centers in 2024. Further, U.S. hospitals performed approximately 2,100 kidney transplants in the first quarter of 2025, each a potential use case for ureteral stents.

Europe’s Established Healthcare Systems Ensure Stable and Mature Market Demand

Europe’s position in the ureteral stents market is solidified by its deeply integrated and well-funded national healthcare systems. In the United Kingdom, the National Health Service (NHS) recorded over 95,000 finished consultant episodes for urology in a single quarter of 2024, indicating immense procedural volume. Germany’s market is defined by its structured reimbursement, with the G-DRG system providing an average payment of €4,200 for a standard ureteroscopy with stent placement in 2024. The region’s professional community is highly engaged, as seen by the over 15,000 delegates who attended the European Association of Urology (EAU) 2024 Congress in Paris.

The specialist workforce is substantial, with France reporting 1,320 practicing urologists in 2024. Regulatory oversight is robust, with 12 new conformity assessments for urological devices completed under the new EU MDR regulations in the first half of 2024. The ureteral stents market sees consistent innovation, with 6 new urology-focused medical device companies receiving series A funding across the EU in 2024. Furthermore, Spain’s public hospitals collectively purchased over 250,000 ureteral stents through public tenders in 2024, showcasing the scale of demand.

Asia Pacific Emerges as the Fastest Growing Ureteral Stents Market Hub

The Asia Pacific region is the most dynamic growth area for the ureteral stents market, driven by expanding healthcare access and a growing local manufacturing base. China’s market is vast, with its National Medical Products Administration (NMPA) granting registration to 18 new domestic models of ureteral stents in 2024 alone. The country’s workforce includes an estimated 45,000 urologists. In Japan, the healthcare system’s capacity is significant, with over 1,500 hospitals equipped with dedicated urology departments as of 2024. India’s private healthcare sector is a major demand driver, with one leading hospital chain performing over 12,000 ureteroscopic procedures in 2024.

Australia contributes with strong research and reimbursement, its Medicare system providing a benefit of AUD 650 for stent insertion procedures. The country in the ureteral stents market also awarded 4 major research grants for novel urological device development in 2024. South Korea’s advanced manufacturing sector has also become a key supplier, exporting over 500,000 medical stents globally in 2024. This combination of rising procedural volumes, increasing government healthcare expenditure, and a burgeoning local innovation ecosystem positions the Asia Pacific region for sustained and rapid market expansion.

Strategic Investments and Acquisitions Accelerate Growth in Ureteral Stents Market

• Boston Scientific Acquires Axonics: In a landmark $3.7 billion deal announced in January 2024, Boston Scientific acquired Axonics, Inc., a company specializing in neuromodulation devices for urinary and bowel dysfunction, strengthening its broader urology portfolio.
• Teleflex Finalizes Acquisition of Palette Life Sciences: Teleflex completed its acquisition of Palette Life Sciences for an upfront cash payment of $600 million in late 2023, with the integration and portfolio consolidation continuing through 2024, enhancing its interventional urology offerings.
• SRS Medical Secures Funding for Novel Stent Technology: In Q2 2024, SRS Medical, a developer of novel urinary devices, announced the closure of a new funding round to advance its Spanner Temporary Prostatic Stent toward broader commercialization.
• UroGen Pharma Announces Public Offering: In February 2024, UroGen, a biotech company focused on uro-oncology, announced a public offering of $100 million in ordinary shares to fund its pipeline, which has implications for interventional urology devices.
• Coloplast Invests in Manufacturing Capacity: Throughout 2024, Coloplast continued its strategic investment to expand production capacity for its interventional urology portfolio, including stents, at its facilities in France and the U.S ureteral stents market.
• Olympus Venture Arm Invests in Digital Urology Startup: The venture capital arm of Olympus made a strategic investment in a digital health startup in Q1 2025 focused on remote monitoring for urology patients, a technology often paired with stent procedures.
• Cook Medical Expands R&D in Urology Division: Cook Medical announced an increased allocation of its R&D budget for 2025 to its urology division, specifically targeting the development of next-generation biodegradable materials for stents.
• Stentra Inc. Receives Bridge Funding: Following FDA clearance for its RELIEF™ stent in late 2023, Stentra Inc. secured bridge funding in early 2024 to support its U.S. commercial launch planned for 2025.
• Laborie Finalizes Acquisition of a Urodynamics Company: In a 2024 transaction, Laborie Medical Technologies acquired a smaller company specializing in urodynamic equipment, which complements its portfolio of diagnostic and interventional urology products.

Top Companies in the Ureteral Stents Market

• Becton, Dickinson and Company
• B. Braun Melsungen AG
• Biomerics
• Boston Scientific Corporation
• Coloplast Ltd.
• Teleflex Incorporated
• Cook Group Incorporated
• Medline Industries Inc.
• Allium Medical Solutions Ltd.
• Merit Medical Systems Inc.
• Olympus Corporation
• Other Prominent Players

Market Segmentation Overview

By Material

• Polymer Ureteral Stents
• Polyurethane Stents
• Silicone Stents
• Hybrid Stents
• Metallic Ureteral Stents

By Application

• Kidney Transplantation
• Tumors
• Urinary Incontinence
• Kidney Stones
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America